






























	 A	 novel	 series	 of	 pyrazolo[1,5‐a]pyrimidine‐3‐carbonitriles	 substituted	 with	 7‐amino,
7‐substituted	 amino	 and	 5‐substituted	 amino	 groups	 was	 synthesized.	 Some	 of	 the	 newly
synthesized	 compounds	 were	 tested	 in	 vitro	 on	 human	 colon	 tumor	 cell	 line	 (HCT116).











Cancer	 is	 defined	 as	 malignant	 growth	 of	 cells.	 Most	 tumors	
arise	 from	 a	 combination	 of	 genetic	 mutations	 in	 the	 cell.	 These	
genetic	changes	lead	to	activation	of	oncogenes	and	suppression	or	
deletion	 of	 tumor	 suppressor	 genes.	 As	 a	 result,	 there	 is	
unregulated	cell	proliferation	and	also	a	delay	in	programmed	cell	
death,	apoptosis	[1].	Most	of	the	clinically	used	antineoplastic	drugs	
aim	 to	suppress	 the	proliferative	process	 (e.g.:	DNA	replication	or	
chromosome	segregation)	[1].	
Pyrazolo[1,5‐a]pyrimidines	 are	 of	 considerable	 chemical	 and	
pharmacological	 importance	 as	 purine	 analogs	 and	 many	
derivatives	 of	 pyrazolo[1,5‐a]pyrimidines	 have	 been	 reported	 to	
exhibit	cytotoxic	activity	[2‐10].	Different	mechanisms	account	for	






In	 the	 present	 study,	 several	 pyrazolo[1,5‐a]pyrimidine	
derivatives,	 bearing	 2‐methylsulphanyl	 group,	 3‐nitrile	 group	 and	
7‐amino	(6a,	6b,	7a‐d,	8	and	9)	or	7‐substituted	amino	group	(14a‐
c)	were	prepared.	Besides,	different	substitutions	were	introduced	
at	 position	 5	 (aromatic	 ring,	 amino	 group	 or	 carbonyl	 group)	
(Scheme	1	and	2).	
Meanwhile,	the	study	aimed	to	synthesize	7‐substituted	amino‐









FT‐IR	 and	 values	were	 represented	 in	 cm‐1.	 1H	NMR	were	 carried	
out	on	Varian	Gemini	200 MHz spectrophotometer,	Microanalytical	
center,	 Cairo	 University,	 Cairo,	 Egypt,	 using	 TMS	 as	 an	 internal	
standard	and	chemical	shifts	were	recorded	in	ppm	on	δ	scale	and	
coupling	 constants	 (J)	 are	 given	 in	 Hz.	 The	 electron	 impact	 (EI)	
mass	 spectra	 were	 recorded	 on	 Shimadzu	 QP‐2010	 plus,	




purified	 and	 dried	 by	 standard	 techniques.	 Elemental	











A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	 (4)	 [11]	 (0.31	 g,	 0.002	 mol),	 the	 appropriate	
substituted	benzylidenemalononitrile	5a‐f	[12‐15]	(0.002	mol)	and	
triethylamine	(2	mL)	in	absolute	ethanol	(20	mL)	was	heated	under	
reflux	 for	 7	 h.	 The	 precipitate	 formed	 was	 filtered,	 dried	 and	
crystallized	from	acetic	acid.	
7‐Amino‐5‐(2‐chlorophenyl)‐2‐methylsulphanyl‐4,5‐dihydro	





















































Reagents: a) ArCH=CH(CN)2 5a-f, triethylamine, ethanol;
b) CH2(CN)2, triethylamine, ethanol;































(m,	 4H,	 Ar‐H),	 9.0	 (s,	 2H,	NH2,	 D2O	 exchangeable).	MS	 (m/z	 (%)):	






















J=7.6	 Hz,	 Ar‐H),	 9.3	 (br	 s,	 2H,	 NH2,	 D2O	 exchangeable).	 MS	 (m/z	














A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	 (4)	 (0.77	 g,	 0.005	 mol),	 malononitrile	 (0.33	 g,	 0.005	
mol)	 and	 triethylamine	 (2	 mL)	 in	 absolute	 ethanol	 (30	 mL)	 was	
heated	under	reflux	 for	10	h.	The	precipitate	 formed	was	 filtered,	
dried	 and	 crystallized	 from	 acetic	 acid.	 Yield:	 26%.	M.p.:	 254‐255	
oC.	FT‐IR	(cm‐1):	3479,	3431,	3373,	3317	(NH2),	2203	(CN).	1H	NMR	
(200	MHz,	DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	5.3	(s,	1H,	H6),	6.7	(s,	






























































Reagents: a) C6H5COCH2COOC2H5, Fusion at 160
oC;
b) CH3COCH2COOC2H5, Fusion at 170
oC (method A), acetic acid (method B);
c) POCl3;




















A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	(4)	(2.31	g,	0.015	mol)	and	ethyl	cyanoacetate	(1.69	g,	
1.70	mL,	0.015	mol)	was	heated	at	160	oC	in	an	oil	bath	for	2	h.	The	
solid	 formed	 was	 triturated	 with	 ethanol	 (10	mL),	 filtered,	 dried	
and	crystallized	from	DMF.	Yield:	93%.	M.p.:	>300	oC.	FT‐IR	(cm‐1):	
3433,	 3319	 (NH/NH2),	 2220	 (CN),	 1650	 (CO).	 1H	NMR	 (200	MHz,	
DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	5.2	(d,	1H,	H6,	J=2.2	Hz),	7.6	(s,	
2H,	NH2,	D2O	exchangeable),	11.9	(br	s,	1H,	NH,	D2O	exchangeable).	






A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	(4)	(2.31	g,	0.015	mol)	and	ethyl	benzoylacetate	(2.88	
g,	2.60	mL,	0.015	mol)	was	heated	at	160	oC	in	an	oil	bath	for	2	h.	
The	 solid	 formed	 was	 triturated	 with	 ethanol	 (10	 mL),	 filtered,	
dried	 and	 crystallized	 from	acetic	 acid.	 Yield:	 67%.	M.p.:	 268‐269	
oC.	 FT‐IR	 (cm‐1):	 3466	 (NH),	 2222	 (CN),	 1718	 (CO).	 1H	NMR	 (200	
MHz,	 DMSO‐d6,	 δ	 ppm):	 2.6	 (s,	 3H,	 SCH3),	 6.2	 (s,	 1H,	 NH,	 D2O	







Method	 A:	 A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 (2.31	 g,	 0.015	 mol)	 and	 ethyl	
acetoacetate	 (1.95	g,	1.90	mL,	0.015	mol)	was	heated	at	170	 oC	 in	
an	 oil	 bath	 for	 2	h.	 The	 solid	 product	was	 triturated	with	 ethanol	
(10	mL),	filtered,	dried	and	crystallized	from	acetic	acid.	
Method	 B:	 A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 (2.31	 g,	 0.015	 mol)	 and	 ethyl	
acetoacetate	(1.95	g,	1.90	mL,	0.015	mol)	 in	glacial	acetic	acid	(50	










A	mixture	 of	 pyrazolo[1,5‐a]pyrimidine	 derivatives	10	 or	 11	
(0.004	 mol)	 and	 phosphorus	 oxychloride	 (20	 mL)	 was	 heated	
under	reflux	 for	7	h.	The	reaction	mixture	was	cooled	and	poured	
gradually	 onto	 crushed	 ice.	 The	 resulting	 product	 was	 filtered,	
dried,	and	crystallized	from	ethanol.	
7‐Chloro‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]	pyrimidine‐















A	mixture	 of	 7‐chloropyrazolo[1,5‐a]pyrimidine	 derivative	12	
(0.60	g,	0.002	mol),	the	appropriate	primary	amine	(0.002	mol)	and	
triethylamine	 (0.50	 mL)	 in	 absolute	 ethanol	 (20	 mL)	 was	 heated	
under	reflux	for	9	h.	The	reaction	mixture	was	concentrated	under	
reduced	pressure,	 and	 the	solid	 formed	upon	 cooling	was	 filtered,	
dried	and	crystallized	from	the	suitable	solvent.	
7‐Cyclohexylamino‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	 (14a):	 (Crystallized	 from	 ethanol).	 Yield:	
60%.	M.p.:	194‐195	oC.	FT‐IR	(cm‐1):	3383	(NH),	2213	(CN).	1H	NMR	
(200	MHz,	DMSO‐d6,	 δ	 ppm):	 1.2‐1.9	 (m,	 11H,	 aliphatic‐H),	 2.7	 (s,	
3H,	SCH3),	7.0	(s,	1H,	H6),	7.5‐8.2	(m,	5H,	Ar‐H),	7.8	(s,	1H,	NH,	D2O	
exchangeable).	 Anal.	 Calcd.	 for	 C20H21N5S:	 C,	 66.08;	 H,	 5.82;	 N,	
19.26.	Found:	C,	66.20;	H,	5.60;	N,	19.39%.	
7‐Anilino‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]pyrimidine‐
3‐carbonitrile	 (14b):	 (Crystallized	 from	 acetic	 acid).	 Yield:	 44%.	
M.p.:	254‐255	oC.	FT‐IR	(cm‐1):	3349	(NH),	2211	(CN).	1H	NMR	(200	
MHz,	 DMSO‐d6,	 δ	 ppm):	 2.8	 (s,	 3H,	 SCH3),	 6.7‐8.3	 (m,	 11H,	 Ar‐H),	
10.3	 (s,	 1H,	 NH,	 D2O	 exchangeable).	 Anal.	 Calcd.	 for	 C20H15N5S:	 C,	
67.20;	H,	4.22;	N,	19.59.	Found:	C,	67.05;	H,	4.12;	N,	19.84%.	
7‐(4‐Methoxyanilino)‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐
a]pyrimidine‐3‐carbonitrile	 (14c):	 (Crystallized	 from	 ethanol).	
Yield:	70%.	M.p.:	192‐193	 oC.	FT‐IR	 (cm‐1):	3305	 (NH),	2211	 (CN).	
1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.8	(s,	3H,	SCH3),	3.8	(s,	3H,	
OCH3),	 6.5‐7.9	 (m,	 10H,	 Ar‐H),	 8.2	 (s,	 1H,	 NH,	 D2O	 exchangeable).	







A	mixture	 of	 5‐chloropyrazolo[1,5‐a]pyrimidine	 derivative	13	
(0.48	g,	0.002	mol),	the	appropriate	primary	amine	(0.002	mol)	and	
triethylamine	 (0.50	 mL)	 in	 absolute	 ethanol	 (20	 mL)	 was	 heated	
under	reflux	for	11	h.	The	reaction	mixture	was	concentrated	under	






(s,	 1H,	H6),	 7.7	 (br	 s,	 1H,	 NH,	 D2O	 exchangeable).	 Anal.	 Calcd.	 for	










IR	 (cm‐1):	 3362	 (NH),	 2217	 (CN).	 1H	 NMR	 (200	MHz,	 DMSO‐d6,	 δ	
ppm):	2.3	(s,	3H,	CH3),	2.7	(s,	3H,	SCH3),	3.8	(s,	3H,	OCH3),	6.0	(s,	1H,	
H6),	7.0	 (d,	2H,	 J=8.7	Hz,	Ar‐H),	 7.3	 (d,	2H,	 J=8.7	Hz,	Ar‐H),	9.9	 (s,	















The	human	colon	 tumor	 cell	 line	 (HCT116)	was	obtained	as	 a	






The	 cytotoxic	 activity	 of	 some	 of	 the	 newly	 synthesized	
compounds	 was	 tested	 in	 vitro	 on	 human	 colon	 tumor	 cell	 line	
(HCT116)	 using	 Sulforhodamine‐B	 stain	 (SRB)	 assay	 according	 to	
the	method	of	Skehan	et	al.	 [17].	Cells	were	plated	in	96‐multiwell	
plate	 (104	 cells/well)	 for	 24	 h	 before	 treatment	 with	 the	 tested	
compounds	to	allow	attachment	of	the	cells	to	the	wall	of	the	plate.	
The	 tested	 compounds	 were	 dissolved	 in	 DMSO	 and	 diluted	 with	
saline	 to	 the	 appropriate	 volume.	 Different	 concentrations	 of	 the	
tested	compound	(0,	1,	2.5,	5	and	10	μg/mL)	were	added	to	the	cell	




0.4%	(w:v)	 Sulforhodamine‐B	 stain	dissolved	with	1%	acetic	 acid.	
Excess	stain	was	removed	by	four	washes	with	1%	acetic	acid	and	
attached	 stain	 was	 recovered	 with	 Tris	 EDTA	 buffer.	 Colour	
intensity	 was	 measured	 in	 ELISA	 reader.	 The	 relation	 between	
surviving	 fraction	 and	 compound	 concentration	 was	 plotted	 and	
IC50	(the	concentration	required	for	50%	inhibition	of	cell	viability)	
was	calculated	for	each	compound	and	results	are	given	in	Table	1.	
Figure	2	 represents	 IC50	in	 μM	of	 the	 synthesized	 compounds	 and	
doxorubicin	against	human	colon	tumor	cell	line	(HCT116)	
	

























and	 2.	 The	 starting	 compound,	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 [11]	was	 reacted	with	 the	appropriate	
substituted	 benzylidenemalononitrile	 5a‐f	 [12‐15]	 to	 afford	 7‐
amino‐2‐methylsulphanyl‐5‐(substituted	 phenyl)‐4,5‐dihydropyra‐
zolo[1,5‐a]pyrimidine‐3,6‐dicarbonitriles	 6a,b	 or	 7‐amino‐2‐
methylsulphanyl‐5‐(substituted	phenyl)pyrazolo[1,5‐a]pyrimidine‐
3,6‐dicarbonitriles	7a‐d.	
The	 reaction	 of	 the	 pyrazole	 derivative	 4	 with	 substituted	
benzylidenemalononitriles	5a‐f	may	proceed	via	initial	nucleophilic	
attack	 by	 the	 exocyclic	 amino	 group	 of	 compound	 4	 on	 the	
activated	 double	 bond	 in	 5a‐f	 to	 form	 a	 Micheal	 adduct.	
Intramolecular	cyclization	of	the	latter	may	result	in	the	formation	















molar	 equivalents	 of	 benzylidenemalononitriles	 5a,b	 or	 by	
increasing	the	time	of	the	reaction	(up	to	15	h)	were	unsuccessful.	
Compound	4	was	 also	 reacted	with	malononitrile	 to	 give	 5,7‐






cyanoacetate,	 ethyl	 benzoylacetate	 and	 ethyl	 acetoacetate	 to	 give	
one	 of	 two	possible	 products;	 the	 5‐oxopyrazolo[1,5‐a]pyrimidine	
or	the	7‐oxo	isomer	(Scheme	4).	The	assignment	of	the	product	as	








acetoacetate	 afforded	 5‐oxopyrazolo[1,5‐a]pyrimidine	 derivatives	
9	 and	11,	 respectively.	Both	 compounds	showed	an	exchangeable	
singlet	 signal	 at	 δ	 11.9	 ppm	 and	 δ	 13.2	 ppm,	 respectively,	
corresponding	to	NH	proton	due	to	tautomerism	with	the	adjacent	
carbonyl	 group.	 The	 7‐oxo	 isomer,	 lacking	 such	 tautomerism,	
should	give	that	signal	at	δ	5‐7	ppm.	
On	 the	 other	 hand,	 the	 reaction	 of	 compound	 4	 with	 ethyl	
benzoylacetate	 afforded	 7‐oxopyrazolo[1,5‐a]pyrimidine	 10.	
Herein,	 1H	 NMR	 of	 compound	 10	 revealed	 the	 presence	 of	 an	
exchangeable	 singlet	 signal	 at	 δ	 6.2	 ppm	 corresponding	 to	 NH	
proton.	
Chlorination	of	compounds	10	and	11	with	POCl3	 followed	by	
nucleophilic	 substitution	 with	 primary	 amines	 afforded	 7‐









The	 response	 parameter	 calculated	was	 the	 IC50	 value,	which	
corresponds	 to	 the	 concentration	 required	 for	 50%	 inhibition	 of	
cell	viability.	The	IC50	in	μM	of	the	tested	compounds	compared	to	
the	 reference	 drug	 are	 shown	 in	 Table	 1	 and	 represented	
graphically	in	Figure	2.	






The	 best	 results	 were	 obtained	 by	 5‐phenyl‐7‐(substituted	
amino)pyrazolo[1,5‐a]pyrimidine	 derivatives	 14a‐c,	 and	 the	






In	 summary,	 a	 novel	 series	 of	 pyrazolo[1,5‐a]pyrimidine‐3‐
carbonitriles	 substituted	with	 7‐amino	 (6‐9),	 7‐substituted	 amino	
(14a‐c)	and	5‐substituted	amino	(15a‐d)	was	synthesized.	Some	of	
the	newly	 synthesized	 compounds	were	 tested	 in	vitro	 on	 human	
colon	 tumor	 cell	 line	 (HCT116).	 Most	 of	 the	 tested	 compounds	
exhibited	good	antitumor	activity,	especially	compound	14a	which	
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